Exome Sequencing Identifies Rare Deleterious Mutations in DNA Repair Genes and as Potential Breast Cancer Susceptibility Alleles

English version České info

Despite intensive efforts using linkage and candidate gene approaches, the genetic etiology for the majority of families with a multi-generational breast cancer predisposition is unknown. In this study, we used whole-exome sequencing of thirty-three individuals from 15 breast cancer families to identify potential predisposing genes. Our analysis identified families with heterozygous, deleterious mutations in the DNA repair genes FANCC and BLM, which are responsible for the autosomal recessive disorders Fanconi Anemia and Bloom syndrome. In total, screening of all exons in these genes in 438 breast cancer families identified three with truncating mutations in FANCC and two with truncating mutations in BLM. Additional screening of FANCC mutation hotspot exons identified one pathogenic mutation among an additional 957 breast cancer families. Importantly, none of the deleterious mutations were identified among 464 healthy controls and are not reported in the 1,000 Genomes data. Given the rarity of Fanconi Anemia and Bloom syndrome disorders among Caucasian populations, the finding of multiple deleterious mutations in these critical DNA repair genes among high-risk breast cancer families is intriguing and suggestive of a predisposing role. Our data demonstrate the utility of intra-family exome-sequencing approaches to uncover cancer predisposition genes, but highlight the major challenge of definitively validating candidates where the incidence of sporadic disease is high, germline mutations are not fully penetrant, and individual predisposition genes may only account for a tiny proportion of breast cancer families.

Vyšlo v časopise: Exome Sequencing Identifies Rare Deleterious Mutations in DNA Repair Genes and as Potential Breast Cancer Susceptibility Alleles. PLoS Genet 8(9): e32767. doi:10.1371/journal.pgen.1002894
Kategorie: Research Article
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.pgen.1002894

Souhrn

Zdroje

1. PharoahPD, LipscombeJM, RedmanKL, DayNE, EastonDF, et al. (2000) Familial predisposition to breast cancer in a British population: implications for prevention. Eur J Cancer 36: 773–779.

2. MikiY, SwensenJ, Shattuck-EidensD, FutrealPA, HarshmanK, et al. (1994) A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 266: 66–71.

3. WoosterR, BignellG, LancasterJ, SwiftS, SealS, et al. (1995) Identification of the breast cancer susceptibility gene BRCA2. Nature 378: 789–792.

4. FordD, EastonDF, StrattonM, NarodS, GoldgarD, et al. (1998) Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet 62: 676–689.

5. MavaddatN, PharoahPD, BlowsF, DriverKE, ProvenzanoE, et al. (2010) Familial relative risks for breast cancer by pathological subtype: a population-based cohort study. Breast Cancer Res 12: R10.

6. ThompsonD, EastonD (2004) The genetic epidemiology of breast cancer genes. J Mammary Gland Biol Neoplasia 9: 221–236.

7. DomchekSM, FriebelTM, SingerCF, EvansDG, LynchHT, et al. (2010) Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA 304: 967–975.

8. Comino-MendezI, Gracia-AznarezFJ, SchiaviF, LandaI, Leandro-GarciaLJ, et al. (2011) Exome sequencing identifies MAX mutations as a cause of hereditary pheochromocytoma. Nat Genet 43: 663–667.

9. JonesS, HrubanRH, KamiyamaM, BorgesM, ZhangX, et al. (2009) Exomic sequencing identifies PALB2 as a pancreatic cancer susceptibility gene. Science 324: 217.

10. GibsonRA, HajianpourA, Murer-OrlandoM, BuchwaldM, MathewCG (1993) A nonsense mutation and exon skipping in the Fanconi anaemia group C gene. Human Molecular Genetics 2: 797–799.

11. GermanJ, SanzMM, CiocciS, YeTZ, EllisNA (2007) Syndrome-causing mutations of the BLM gene in persons in the Bloom's Syndrome Registry. Hum Mutat 28: 743–753.

12. StrathdeeCA, GavishH, ShannonWR, BuchwaldM (1992) Cloning of cDNAs for Fanconi's anaemia by functional complementation. Nature 356: 763–767.

13. GavishH, dos SantosCC, BuchwaldM (1993) A Leu554-to-Pro substitution completely abolishes the functional complementing activity of the Fanconi anemia (FACC) protein. Human Molecular Genetics 2: 123–126.

14. The 1000 Genomes Project Consortium (2010) A map of human genome variation from population-scale sequencing. Nature 467: 1061–1073.

15. CouchFJ, JohnsonMR, RabeK, BoardmanL, McWilliamsR, et al. (2005) Germ line Fanconi anemia complementation group C mutations and pancreatic cancer. Cancer Research 65: 383–386.

16. WangW (2007) Emergence of a DNA-damage response network consisting of Fanconi anaemia and BRCA proteins. Nat Rev Genet 8: 735–748.

17. HeyerWD, EhmsenKT, LiuJ (2010) Regulation of homologous recombination in eukaryotes. Annu Rev Genet 44: 113–139.

18. van der HeijdenMS, YeoCJ, HrubanRH, KernSE (2003) Fanconi anemia gene mutations in young-onset pancreatic cancer. Cancer Research 63: 2585–2588.

19. BerwickM, SatagopanJM, Ben-PoratL, CarlsonA, MahK, et al. (2007) Genetic heterogeneity among Fanconi anemia heterozygotes and risk of cancer. Cancer Research 67: 9591–9596.

20. BarisHN, KedarI, HalpernGJ, ShohatT, MagalN, et al. (2007) Prevalence of breast and colorectal cancer in Ashkenazi Jewish carriers of Fanconi anemia and Bloom syndrome. Isr Med Assoc J 9: 847–850.

21. SealS, ThompsonD, RenwickA, ElliottA, KellyP, et al. (2006) Truncating mutations in the Fanconi anemia J gene BRIP1 are low-penetrance breast cancer susceptibility alleles. Nature Genetics 38: 1239–1241.

22. SokolenkoAP, IyevlevaAG, PreobrazhenskayaEV, MitiushkinaNV, AbyshevaSN, et al. (2011) High prevalence and breast cancer predisposing role of the BLMc.1642 C>T (Q548X) mutation in Russia. International Journal of Cancer doi: 10.1002/ijc.26342.

23. GruberSB, EllisNA, ScottKK, AlmogR, KolachanaP, et al. (2002) BLM heterozygosity and the risk of colorectal cancer. Science 297: 2013.

24. ClearySP, ZhangW, Di NicolaN, AronsonM, AubeJ, et al. (2003) Heterozygosity for the BLM(Ash) mutation and cancer risk. Cancer Res 63: 1769–1771.

25. WalshT, LeeMK, CasadeiS, ThorntonAM, StraySM, et al. (2010) Detection of inherited mutations for breast and ovarian cancer using genomic capture and massively parallel sequencing. Proceedings of the National Academy of Sciences of the United States of America 107: 12629–12633.

26. ZollnerS, PritchardJK (2007) Overcoming the winner's curse: estimating penetrance parameters from case-control data. Am J Hum Genet 80: 605–615.

27. MeindlA, HellebrandH, WiekC, ErvenV, WappenschmidtB, et al. (2010) Germline mutations in breast and ovarian cancer pedigrees establish RAD51C as a human cancer susceptibility gene. Nature Genetics 42: 410–416.

28. LovedayC, TurnbullC, RamsayE, HughesD, RuarkE, et al. (2011) Germline mutations in RAD51D confer susceptibility to ovarian cancer. Nature Genetics 43: 879–882.

29. ThompsonER, BoyleSE, JohnsonJ, RylandGL, SawyerS, et al. (2012) Analysis of RAD51C germline mutations in high-risk breast and ovarian cancer families and ovarian cancer patients. Human Mutation 33: 95–99.

30. OsborneRH, HopperJL, KirkJA, Chenevix-TrenchG, ThorneHJ, et al. (2000) kConFab: a research resource of Australasian breast cancer families. Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer [letter]. med j aust 172: 463–464.

31. BerryDA, IversenESJr, GudbjartssonDF, HillerEH, GarberJE, et al. (2002) BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 20: 2701–2712.

32. BaxterSW, ChoongDY, EcclesDM, CampbellIG (2001) Polymorphic variation in CYP19 and the risk of breast cancer. Carcinogenesis 22: 347–349.

33. LiH, DurbinR (2009) Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics 25: 1754–1760.

34. McKennaA, HannaM, BanksE, SivachenkoA, CibulskisK, et al. (2010) The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Research 20: 1297–1303.

35. McLarenW, PritchardB, RiosD, ChenY, FlicekP, et al. (2010) Deriving the consequences of genomic variants with the Ensembl API and SNP Effect Predictor. Bioinformatics 26: 2069–2070.

36. RiosD, McLarenWM, ChenY, BirneyE, StabenauA, et al. (2010) A database and API for variation, dense genotyping and resequencing data. BMC Bioinformatics 11: 238.

37. StensonPD, BallEV, HowellsK, PhillipsAD, MortM, et al. (2009) The Human Gene Mutation Database: providing a comprehensive central mutation database for molecular diagnostics and personalized genomics. Hum Genomics 4: 69–72.

38. NgPC, HenikoffS (2001) Predicting deleterious amino acid substitutions. Genome Research 11: 863–874.

39. AdzhubeiIA, SchmidtS, PeshkinL, RamenskyVE, GerasimovaA, et al. (2010) A method and server for predicting damaging missense mutations. Nat Methods 7: 248–249.